# Regulation of Proliferation and Differentiation of Myoblasts Derived from Adult Mouse Skeletal Muscle by Specific Isoforms of PDGF

Zipora Yablonka-Reuveni,\* Thomas M. Balestreri,\* and Daniel F. Bowen-Pope<sup>‡</sup>

\* Department of Biological Structure; and <sup>‡</sup>Department of Pathology, School of Medicine, University of Washington, Seattle, Washington 98195

Abstract. The expression of receptors and the mitogenic response to PDGF by C2 myoblasts, derived from adult mouse skeletal muscle, was investigated. Employing <sup>125</sup>I-PDGF binding assays, we showed that the cells exhibit high level binding of PDGF-BB (~165 × 10<sup>3</sup> molecules/cell at saturation) and much lower binding of the PDGF-AA and PDGF-AB (6-12 × 10<sup>3</sup> molecules/cell at saturation). This indicates that the C2 myoblasts express high levels of PDGF receptor  $\beta$ -subunits and low levels of  $\alpha$ -subunits. PDGF-BB enhances the proliferation of C2 cells maintained in

**HROUGHOUT** embryogenesis of skeletal muscle, myogenic precursors proliferate and eventually give rise to terminally differentiated, fusion-capable myoblasts. During postnatal growth, the myogenic precursor cells are still in their proliferative phase (Moss and Leblond, 1971) but in adult muscle, these cells are mitotically quiescent (Schultz et al., 1978). The myogenic precursor cells in the adult, which are often referred to as satellite cells, can reinitiate proliferative activity after muscle injury, and their progeny fuse into multinucleated fibers (Snow, 1977; Mauro, 1979; reviewed in Campion, 1984). Adult satellite cells also become mitotically active upon culturing, displaying a program of proliferation and differentiation similar to that of embryonic myoblasts (Bischoff, 1974; Yablonka-Reuveni et al., 1987). Studies on adult-derived myoblasts have identified several physiological growth factors that could regulate the quiescent and proliferative states of satellite cells. These factors include FGF, insulin-like growth factors, and transforming growth factor  $\beta$  (Allen et al., 1984; Allen and Boxhorn, 1989; Bischoff, 1986; Clegg et al., 1987; Jennische et al., 1987; DiMario and Strohman, 1988; reviewed in Florini and Magri, 1989).

PDGF has been implicated as an important mediator of wound healing and tissue repair (reviewed in Ross et al., 1986), but its role during skeletal muscle regeneration has not been fully investigated. PDGF is a potent mitogen for many mesenchymal cells including fibroblasts and smooth muscle cells (reviewed in Ross et al., 1986; Heldin and Westermark, 1989) and was recently also shown to play a 2% FCS by about fivefold. PDGF-AB had a moderate effect on cell proliferation (less than twofold) and PDGF-AA had no effect. Inverse effects of PDGF isoforms on the frequency of differentiated myoblasts were observed; the frequency of myosin-positive cells was reduced in the presence of PDGF-BB while PDGF-AA and PDGF-AB had no effect. PDGF may thus act to increase the number of myoblasts that participate in muscle regeneration following muscle trauma by stimulating the proliferation and by inhibiting the differentiation of myogenic cells.

role in the proliferation and differentiation of specific cells in the glial cell lineage (Hart et al., 1989; reviewed in Heldin and Westermark, 1989). PDGF can also elicit other biological responses, including increased metabolic rates and chemotaxis (reviewed in Ross et al., 1986; Heldin and Westermark, 1989). Two homodimeric forms of PDGF (AA and BB) and one heterodimeric form (AB) have been purified from mammals and are functionally active (Bowen-Pope et al., 1989). Although PDGF was initially isolated from platelets and megakaryocytes, it is now well established that other cell types are also capable of producing this growth factor (reviewed in Ross et al., 1986; Heldin and Westermark, 1989). There are at least two separate PDGF receptor proteins which differ in their specificities for the two chains of PDGF (Hart et al., 1988; Heldin et al., 1988). According to the model proposed by Seifert et al. (1989), the two different receptor proteins function as subunits (designated  $\alpha$  and  $\beta$ ) which dimerize to form three distinct receptors ( $\alpha \alpha$ ,  $\alpha \beta$ ,  $\beta\beta$ ) (Seifert et al., 1989; Heldin et al., 1989; Hammacher et al., 1989). PDGF-AA can only bind to the  $\alpha\alpha$  receptor, PDGF-AB can bind to both  $\alpha\alpha$  and  $\alpha\beta$  receptor, and PDGF-BB can bind to all three receptor subunit combinations:  $\alpha \alpha$ ,  $\alpha\beta$ , and  $\beta\beta$ .

In this study, we analyzed the effect of the three PDGF dimers on the myogenic cell line C2, which was derived from normal adult mouse muscle (Yaffe and Saxel, 1977) and is presumably derived from satellite cells. We chose to study a cell line rather than primary cells in order to avoid the complexity introduced by fibroblast-like cells which are present

in primary cultures and are capable of binding PDGF (Yablonka-Reuveni et al., 1988, 1990; manuscript in preparation). We used the C2 cell line because it has been demonstrated to be able to participate in muscle regeneration in vivo (Partridge et al., 1988). Nevertheless, we recognize that the behavior of the C2 cells in vitro may not completely reproduce the behavior of the satellite cells in vivo.

We were able to demonstrate significant binding of all three PDGF dimers, with a much higher number of PDGF-BB molecules bound at saturation compared to PDGF-AA and PDGF-AB. PDGF-BB also significantly promoted cell proliferation and depressed the frequency of differentiated myoblasts. PDGF-AB had only a small effect on cell proliferation, and no effects of PDGF-AA could be documented. PDGF-BB may thus play a role during muscle regeneration by increasing the number of proliferating myoblasts available for repair following muscle trauma.

# Materials and Methods

#### Cell Culture

C2 cells, originally isolated from adult mouse skeletal muscle (Yaffe and Saxel, 1977), were kindly provided by D. Yaffe (The Weizmann Institute of Science, Rehovot, Israel). Cells were maintained at 37.5°C in water-saturated air containing 5% CO<sub>2</sub>, using gelatin-coated, 100-mm tissue culture dishes. Proliferation medium consisted of MEM (Gibco Laboratories, Grand Island, NY) containing 20% FCS (HyClone Laboratories, Logan, UT), 0.5% chicken embryo extract, penicillin, and streptomycin at 10<sup>5</sup> U per liter each. It should be noted that the cells can differentiate in this medium when they reach very high cell density. For subculturing, sparse cells were exposed to 1.25% trypsin (Gibco Laboratories) for ~30 min at 37°C. Cells were then mechanically triturated, filtered through lens paper to eliminate cell aggregates (Yablonka-Reuveni and Nameroff, 1987), counted in a hemocytometer, and further cultured as described below.

#### **PDGF Binding and Competition Assays**

Highly purified PDGF-AB free of contaminating PDGF-AA or PDGF-BB was kindly provided by E. Raines and R. Ross (Department of Pathology, University of Washington) and was prepared as previously reported (Raines and Ross, 1982; Seifert et al., 1989). Highly purified recombinant PDGF-AA and PDGF-BB were produced from yeast as previously described (Bowen-Pope et al., 1989; Seifert et al., 1989). These recombinant molecules were kindly provided by M. Murray and J. Forstrom (ZymoGenetics, Seattle, Washington). Radioiodination of the three PDGF forms, saturation binding of <sup>125</sup>I-PDGF to the cells, and competition assays were performed as previously described (Bowen-Pope et al., 1989).

C2 cells used for the assays were passaged into gelatin-coated, 24-well trays (well diameter = 16 mm) at a density of  $5 \times 10^4$  cells/well and maintained for 1-2 d in proliferation medium until  $\sim$ 70% confluent. About 16-20 h before assaying for PDGF binding, medium was changed to MEM containing 2% FCS and antibiotics. This was done in order to reduce the amount of PDGF in the medium, which could bind to the PDGF receptors before the binding assay. C2 cells maintained in low serum differentiate earlier than cells in proliferation medium (detailed in Results); however, at the time of the binding assays over 98% of the cells were not differentiated, and no myotubes were observed. For binding measurements, cultures were exposed at 4°C for 3 h to increasing amounts of <sup>125</sup>I-PDGF in binding buffer (Ham's medium F-12 buffered at pH 7.4 with 25 mM HEPES and supplemented with 0.25% BSA). Cultures were then rinsed with cold binding buffer, and cell-bound <sup>125</sup>I-PDGF was solubilized with 1% Triton X-100 containing 0.1% BSA and measured with a gamma counter. Nonspecific binding of PDGF, determined by preincubating cells with an excess of unlabeled PDGF (100 ng/ml), was subtracted to determine the amount of specifically bound label. Cell numbers were determined on wells that were treated as those for binding measurements. Cells were trypsinized and then counted, using an electronic particle counter. All measurements were done on triplicate wells. For competition binding, the cells were rinsed once with cold binding buffer and then incubated in 1 ml of binding buffer containing increasing amounts of unlabeled PDGF-AA or PDGF-BB, followed by incubation with binding buffer containing 2 ng/ml <sup>125</sup>I-PDGF-BB. Cells incubated with 2 ng/ml <sup>125</sup>I-PDGF-BB only were used to determine control binding. Measurement of nonspecific binding and further analysis were as described for binding assays.

#### <sup>3</sup>H-thymidine Incorporation

To assay the effect of PDGF on proliferation, cells were passaged into gelatin-coated, 24-well trays and plated, unless noted otherwise, at a density of  $10^3$ -2.5 × 10<sup>3</sup> per well. Cells were maintained for 1 d in proliferation medium and then received a medium consisting of 2% FCS plus antibiotics in MEM (2% FCS medium). Control wells received no further additives, whereas experimental wells received either PDGF-AA at 20 ng/ml, PDGF-AB at 5 ng/ml, or PDGF-BB at 20 ng/ml. To ensure ample supply of PDGF, the medium and additives were replaced every 24 h. At daily intervals (before the next medium change), cells were pulsed for 2 h with 1  $\mu$ C/ml [<sup>3</sup>H]thymidine (<sup>3</sup>H-TdR; New England Nuclear, Boston, MA specific activity 6.7 Ci/mmole). At the end of the labeling period, cells were rinsed  $3 \times$  with ice-cold MEM. This was followed by the addition of 1 ml of 5% ice-cold TCA, in which the cells were maintained overnight at 4°C. Cells were then rinsed  $2 \times$  with ice-cold 5% TCA and dissolved in 0.5 ml of 0.5 N NaOH at 37°C. Plates were then subjected to vigorous rotating for 15-30 min to ensure complete detachment of cells, and the NaOH suspensions were transferred into scintillation vials. Radioactivity was measured using 10 ml of ScintiVerse II (Fisher Scientific Co., Pittsburgh, PA). All measurements were made on triplicate wells.

#### **Detection of Terminally Differentiated Myoblasts**

Cells were cultured on gelatin-coated, 35-mm dishes, employing proliferation medium, and then exposed to 2% FCS medium with or without PDGF, as described above for <sup>3</sup>H-TdR incorporation. Cultures were initiated at a density of 5-10  $\times$  10<sup>3</sup> cells per dish. Terminally differentiated cells were detected employing indirect immunofluorescence as previously described (Yablonka-Reuveni and Nameroff, 1987; Yablonka-Reuveni et al., 1987) and using the mAb MF20 which is specific for sarcomeric myosin. This antibody, which was originally prepared by Bader et al. (1982) and discussed in further publications (Zadeh et al., 1986; Saad et al., 1987), was obtained from the Developmental Studies Hybridoma Bank (maintained by a contract from NICHD (NOI-HD-6-2915). Growth medium of hybridomaproducing MF20, the source of the antibody, was diluted 1:5 in 0.05 M Tris, 0.9% NaCl, 1% normal goat serum, pH 7.4. The secondary antibody was fluorescein-labeled goat anti-mouse IgG (Organon Teknika-Cappel, Malvern, PA) and was diluted to 1:50. After the antibody reaction, nuclei were stained with ethidium bromide and counted, using fluorescence microscopy to determine total cell numbers (including cells that fused into myotubes) and the proportion of terminally differentiated cells (including cells that fused into myotubes). Nuclei were labeled by exposing cultures for 5 min to two to three drops of ethidium bromide (2  $\mu$ g/ml). Cultures were then rinsed extensively with 0.05 M Tris, 0.9% NaCl, 0.05% Tween 20, pH 7.4, and received a final rinse with 0.05 M Tris, pH 7.4. Cultures were mounted with 90% glycerol containing antifading agent (Yablonka-Reuveni et al., 1987) and observed with a Zeiss photomicroscope equipped for epifluorescence. The bright red fluorescence of the nuclei could be visualized alone using the rhodamine filters or simultaneously with the antibody stain, employing the fluorescein filters. Ten random fields per 35-mm dish were analyzed, using duplicate dishes.

### Results

#### C2 Myoblasts Express Different Numbers of Binding Sites for the Three PDGF Isoforms

Using <sup>125</sup>I-PDGF, we determined the saturation binding curves for the three different PDGF dimers, as shown in Fig. 1. The saturation binding of PDGF-AA is  $12 \times 10^3$  bound molecules per cell, that of PDGF-AB is  $6.5 \times 10^3$  bound molecules per cell, and that of PDGF-BB is  $165 \times 10^3$ bound molecules per cell. Although high-affinity binding of all three dimers is detected, the number of PDGF-BB bind-



ing sites is, thus, many fold greater than that of the PDGF-AA or PDGF-AB binding sites.

According to the PDGF receptor model proposed by Seifert et al. (1989), PDGF-BB can bind to all three receptor types, whereas PDGF-AA can only bind to one receptor type ( $\alpha\alpha$ ). This model predicts that the portion of PDGF-BB binding to  $\alpha\alpha$  and  $\alpha\beta$  receptors can be eliminated by incubation with PDGF-AA to occupy the  $\alpha$ -subunits. This allows us to use a competition binding protocol to test whether most of the PDGF receptors consist of  $\beta\beta$  dimers, as implied by the results of the saturation binding. The results of such competition assays (Fig. 2) indicate that PDGF-AA competes for <20% of the <sup>125</sup>I-PDGF-BB binding sites and confirm that most of the PDGF receptors present on C2 cells are  $\beta\beta$ receptors.

#### PDGF-AA, PDGF-AB, and PDGF-BB Differentially Affect the Proliferation of C2 Myoblasts

Mitogens contained in proliferation medium could obscure the specific effects of PDGF isoforms on myoblast proliferation. Therefore, to analyze such effects, we maintained the cells in 2% FCS medium to reduce the mitogens contributed by the basal medium. Incorporation of 3H-TdR after 24 h in this medium is reduced by about three- to fourfold and is further reduced by five- to sixfold by 48 h compared to cultures grown in proliferation medium (data not shown). Fusion into myotubes occurs in cultures maintained in the 2% FCS medium earlier than in cultures maintained in proliferation medium, even though cells in 2% FCS medium are less crowded (Fig. 3, a and c). However, differentiation of C2 cells in the 2% FCS is cell density dependent and can be delayed by reducing cell density. Therefore, to minimize differentiation while studying proliferation, cultures were initiated with low cell density as described under Materials and Methods, unless otherwise noted.



Figure 1. Saturation binding of PDGF-AA, PDGF-AB, and PDGF-BB to C2 myoblasts. Cells were cultured in proliferation medium. 24 h before the PDGF binding assay, the medium was replaced with MEM supplemented with 2% FCS to reduce exogenous PDGF. The plotted values represent the average specific binding to triplicate wells, and standard error was <10%. Cell numbers were determined on parallel triplicate wells.

*Figure 2.* Competition binding of PDGF-AA and PDGF-BB for <sup>125</sup>I-PDGF-BB binding. After initial culturing in proliferation medium, cells were shifted to MEM supplemented with 2% FCS for 20 h. Cells were then incubated with increasing amounts of unlabeled PDGF-AA or PDGF-BB, followed by an incubation with 2 ng/ml <sup>125</sup>I-PDGF-BB. Controls were incubated with <sup>125</sup>I-PDGF-BB alone. Plotted values represent specific binding as a percent of control. Standard error was <10% for triplicate wells.



Figure 3. Effect of serum and PDGF-BB on proliferation and fusion of C2 cells. Cells were cultured at  $5 \times 10^3$  cells per 35-mm dish in proliferation medium. After 24 h, medium was replaced with fresh proliferation medium (a and b), 2% FCS medium (c and d), and 0.25 mg/ml BSA medium (e and f). Only cultures b, d, and f received 20 ng/ml PDGF-BB. Medium, without or with PDGF, was replaced every 24 h thereafter. Representative phase contrast micrographs of live cultures were taken 96 h after initial culturing. Bar, 30  $\mu$ m.

A summary of the effect of PDGF isoforms on 3H-TdR incorporation is shown in Fig. 4. In these experiments, cultures were initiated with standard cell density  $(2.5 \times 10^3)$ cells per well), and the three PDGF isoforms were added at the time that cultures were exposed to the 2% FCS. During the first day in 2% FCS, no differences in <sup>3</sup>H-TdR incorporation were observed in the proliferation of control cells or cells that received PDGF. However, during consecutive days in culture, the effect of PDGF-BB on cell proliferation became clear: proliferation increased by over twofold on the second day of culture and by almost fivefold on the third day, compared to control cultures. PDGF-AB had a small effect on cell proliferation and enhanced proliferation by 1.2- and 1.5-fold on the second day and the third day of culture, respectively. No effect of PDGF-AA on the level of proliferation could be documented under these conditions.

We could not document any significant effect of PDGF-BB

on <sup>3</sup>H-TdR incorporation when added to C2 cells maintained in 20% FCS (for morphological appearance of cells maintained in 20% FCS without or with PDGF-BB, see Fig. 3, a and b). However, the effect of PDGF-BB on the proliferation of C2 cells was not limited to cells maintained in 2% FCS. A very dramatic response to this isoform was observed when C2 cells were maintained in MEM containing only 0.25 mg/ml BSA (Fig. 3, e and f). Under these conditions, PDGF-BB increased the cell number and resulted in a 3.5-4.5-fold increase in <sup>3</sup>H-TdR incorporation in cultures maintained in BSA plus PDGF-BB, compared to cultures maintained in BSA alone (data not shown). Most of the cells in cultures lacking PDGF were bipolar (presumably, differentiated cells) or fused into small, multinucleated myotubes. Cultures that received PDGF-AA morphologically resembled cultures lacking PDGF. Cultures that received PDGF-AB were intermediate in cell number and morphology (data





Figure 4. Effect of the different isoforms of PDGF on <sup>3</sup>H-TdR incorporation. Cells were cultured at  $2.5 \times 10^3$  cells/16-mm well in proliferation medium for 24 h, followed by an exposure to 2% FCS in MEM for various lengths of time in the absence or presence of the different PDGF isoforms. PDGF-AA, PDGF-AB, and PDGF-BB were added at 20, 5, and 20 ng/ml, respectively. The 2% FCS medium with or without PDGF was replaced every 24 h. 2 h before cell harvesting, the cultures were exposed to <sup>3</sup>H-TdR at 1  $\mu$ C/ml, and the extent of <sup>3</sup>H-TdR incorporation into TCA precipitable material was determined. Plotted values represent the average of triplicate wells. Standard error was <5%.

not shown). For further studies, we used 2% FCS medium and not BSA medium since many cells detached (presumably died) in the BSA medium, making it unsuitable for longer term studies of proliferation and differentiation.

#### The Manifestation of PDGF-BB Effect on Proliferation Is Cell Density Dependent

In the experiments described in Fig. 4, the effect of PDGF-BB on cell proliferation was not observed until the second day in 2% FCS. This could mean that the 2% FCS medium contains enough PDGF or other mitogens to support the ini-



Figure 5. Effect of PDGF-BB on proliferation of crowded C2 myoblasts. Cells were cultured at  $7.5 \times 10^3$  cells/16-mm well in proliferation medium and further treated as described in Fig. 2. Standard error was <5%.

Figure 6. Effect of the three PDGF isoforms on proliferation of sparse C2 myoblasts. Cells were cultured at  $10^3$  cells/16-mm well in proliferation medium and further treated as described in Fig. 2. Standard error was <5%.

tial cell proliferation, but that when cells increase in numbers, they deplete the endogenous mitogen(s), and only at this stage would the effect of exogenous PDGF be detected. To test this possibility, we examined <sup>3</sup>H-TdR incorporation in response to PDGF in cultures initiated with high and low cell densities. As shown in Fig. 5, when starting cell densities were higher than those described for Fig. 4, the effect of PDGF-BB was already apparent after 36–48 h in 2% FCS. By contrast, the effect of the added PDGF-BB was delayed even further (to day 4) in experiments where the cultures were initiated with fewer cells (Fig. 6). This supports the notion that 2% FCS can sustain proliferation of sparse cells but that PDGF becomes limiting when cells reach higher densities and deplete endogenous PDGF or other mitogens.

 Table I. Frequency of Myosin-positive Cells in C2 Cultures

 Treated with PDGF

PDGF added	48 h in 2% FCS			72 h in 2% FCS		
	Total nuclei	Nuclei in myosin + cells	% Differ- entiation	Total nuclei	Nuclei in myosin+ cells	% Differ- entiation
Experiment 1						
None	812	65	8.0	906	278	30.6
AA	720	55	7.6	872	292	33.4
AB	889	70	7.8	983	269	27.3
BB	949	29	3.0	1231	126	10.2
Experiment 2						
None	560	27	4.8	601	115	19.1
AA	504	31	6.1	559	109	19.4
AB	607	24	3.9	640	138	21.5
BB	653	9	1.3	954	65	6.8

Cells were fixed at indicated time points and identification of differentiated cells was done immunohistochemically, using an antibody against sarcomeric myosin. Nuclei within myosin-positive cells (and multinucleated myotubes) and myosin-negative cells were visualized using ethidium bromide. Nuclear counts were made on duplicate 35-mm dishes, screening 10 random fields per dish.

#### The Frequency of Differentiated Myoblasts Is Reduced in the Presence of PDGF-BB

Various studies have indicated that mammalian myoblasts differentiate in response to reducing the serum concentration in the growth medium (i.e., Yaffe, 1973; Yaffe and Saxel, 1977; Clegg et al., 1987; Fig. 3, this study). Our preliminary studies indicated that C2 cultures maintained in 2% FCS in the presence of PDGF-BB exhibit fewer myotubes than in the absence of the factor (Fig. 3, c and d). To further investigate the effect of PDGF on C2 cells, we analyzed the frequency of terminally differentiated cells in control and PDGFtreated cultures maintained in 2% FCS medium. Cultures were initiated in proliferation medium then shifted to 2% FCS medium with or without PDGF as for 3H-TdR incorporation assays. Differentiated cells were detected with an antibody against sarcomeric myosin (MF20). Total cell numbers, the number of differentiated mononucleated cells, and the number of cells fused into multinucleated fibers were determined by counting nuclei. A summary of this study is shown in Table I. In all cases, PDGF-BB increased the total number of nuclei and decreased the number of nuclei in differentiated cells.

# Discussion

Our studies with the C2 myogenic line derived from adult mouse skeletal muscle demonstrate that these myoblasts express receptors for PDGF and that PDGF exerts a mitogenic effect on these cells. Of the three known PDGF dimers, the BB isoform has the greatest number of binding sites on the C2 myoblasts and is the most potent in promoting <sup>3</sup>H-TdR incorporation and in reducing the frequency of terminally differentiated myoblasts. Whereas PDGF-AA can bind to the cells, the number of binding sites is much lower than that of PDGF-BB and no mitogenic effect can be demonstrated. PDGF-AB binds to the C2 cells at a level similar to that of PDGF-AA and exerts a very slight mitogenic effect on the cells. According to the model proposed by Seifert et al. (1989), PDGF-AA can only bind to the  $\alpha\alpha$  receptor, PDGF-AB can bind to the  $\alpha\alpha$  and the  $\alpha\beta$  receptors, and PDGF-BB can bind to all three receptor combinations:  $\alpha \alpha$ ,  $\alpha \beta$ , and  $\beta \beta$ . The saturation binding experiments indicate that the C2 cells express much higher levels of  $\beta$ - than  $\alpha$ -receptor subunits. This is supported by the competition experiment (Fig. 2) which demonstrates that the  $\alpha$ -subunit accounts for <20% of total receptor subunits. Other adult cell types also express many more  $\beta$ - than  $\alpha$ -subunits and respond much better to PDGF-BB than to PDGF-AA (e.g., see Seifert et al., 1989). Whether this difference in response results from quantitative differences in signalling through the different receptor proteins or merely reflects quantitative differences in level of receptor subunit expression is not yet clear.

The saturation binding experiments demonstrate that C2 cells maintained in 2% FCS for 16–20 h express receptors to PDGF-BB. However, the response to PDGF-BB, as measured by <sup>3</sup>H-TdR incorporation, is delayed beyond 24 h in cultures initiated at low cell densities. This delay in response may reflect the presence of enough mitogens in 2% FCS to support the initial cell proliferation but that proliferation becomes dependent on exogenous PDGF when these mitogens have been depleted by more crowded cells. In contrast to the

stimulation of proliferation, the number of differentiated myoblasts is reduced in the presence of PDGF-BB. Little or no differentiation occurs during the first 24 h, even in the absence of PDGF. As cells become more crowded, mitogens become limiting, and increasing numbers of myoblasts differentiate and exit the cell cycle in the absence of PDGF. In the presence of PDGF, fewer cells differentiate, and more cells are available for the next round of cell division. If PDGF operates by suppressing differentiation rather than by promoting proliferation, then another mitogen needs to be present in sufficient amounts in the mitogen-depleted cultures in order to promote proliferation. It is possible that PDGF-BB functions both as a mitogen and as a suppressor of cell differentiation, and the effect of PDGF becomes pronounced through the combined effects of decreased frequency of withdrawal from the cell cycle and increased number of undifferentiated cells available for the next round of cell division.

The binding of PDGF to skeletal muscle cells and the response of these cells to PDGF has been studied previously, but only briefly. Linkhart et al. (1982) mentioned that the mouse myoblast cell line MM14, which, like the C2 cell line, was derived from adult muscle, did not respond to PDGF (primarily AB isoform). More recent studies on these MM14 myoblasts indicate that they do not bind PDGF-BB (Bowen-Pope and Olwin, unpublished results). Bischoff (1986), using isolated intact muscle fibers containing satellite cells in their native position under the basement membrane, concluded that the addition of PDGF did not activate the proliferation of quiescent satellite cells. This study did not investigate the effects of PDGF following the initial activation of satellite cells, and employed PDGF-AB, which is also a poor mitogen for C2 cells. By contrast, studies of cultured avian myoblasts have indicated a potential role for PDGF during certain stages of myogenesis. Venkatasubramanian and Solursh (1984) showed that PDGF (the AB type) can induce a migratory response in a myogenic cell population from avian limb buds. We have previously demonstrated a significant binding of PDGF-AB to myogenic cultures from adult chicken skeletal muscle but not to such cultures from 10 day embryos (Yablonka-Reuveni et al., 1988, 1990). Thus, it is possible that myoblasts from different developmental and physiological stages respond differently to PDGF. Another intriguing possibility is that PDGF, which is a chemoattractant for a variety of cells (Seppä et al., 1982; Grotendorst et al., 1982; reviewed in Ross et al., 1986), as well as for cells in avian limb buds (Venkatasubramanian and Solursh, 1984), may affect the migration of satellite cells. Such migration from regions distal to the injury would be an additional source for myoblasts during regeneration (Mauro, 1979; Schultz et al., 1988; Watt et al., 1987).

In summary, the experiments presented in this study using a rodent satellite cell-derived cell line provide the first direct evidence that PDGF can regulate myoblast proliferation and differentiation in vitro. It is thus possible that PDGF has a role in increasing the number of myoblasts during skeletal muscle regeneration by stimulating proliferation and/or inhibiting differentiation.

We thank Drs. D. Yaffe for the C2 cells; E. Raines and R. Ross for the PDGF-AB; M. Murray and J. Forstrom and PDGF-AA and PDGF-BB; and A. Reuveni for advice on graph preparation. We are also grateful to

J. C. Dennis and R. S. Hartley for helpful comments on the manuscript, and to M. Wright for editing the manuscript.

This work was supported by grants from the American Heart Association Washington Affiliate (Z. Yablonka-Reuveni), the University of Washington Graduate School Research Fund (Z. Yablonka-Reuveni) and the National Institutes of Health (AR39677 to Z. Yablonka-Reuveni and GM35501 to D. F. Bowen-Pope). The study was done during the tenure of an established investigatorship of the American Heart Association (D. F. Bowen-Pope). T. M. Balestreri was a University of Washington Medical Student Research Program Trainee.

Received for publication 19 February 1990 and in revised form 30 May 1990.

Note Added in Proof. Jin et al (1990) have recently reported similar observations using rat myoblasts.

#### References

- Allen, R. E., and L. K. Boxhorn. 1989. Regulation of skeletal muscle satellite cell proliferation and differentiation by transforming growth factor-beta, insulin-like growth factor I, and fibroblast growth factor. J. Cell. Physiol. 38:311-315.
- Allen, R. E., M. V. Dodson, and L. S. Luiten. 1984. Regulation of skeletal muscle satellite cell proliferation by bovine pituitary fibroblast growth factor. *Exp. Cell Res.* 152:154-160.
- Bader, D., T. Masaki, and D. A. Fischman. 1982. Biochemical analysis of myosin heavy chain during avian myogenesis in vivo and in vitro. J. Cell Biol. 95:763-770.
- Bischoff, R. 1974. Enzymatic liberation of myogenic cells from adult rat muscle. Anat. Rec. 180:645-662.
- Bischoff, R. 1986. Proliferation of muscle satellite cells on intact myofibers in culture. Dev. Biol. 115:129-139.
- Bischoff, R. 1989. Analysis of muscle regeneration using single myofibers in culture. Med. Sci. Sports Exercise. 21:S164–S172.
- Bowen-Pope, D. F., C. E. Hart, and R. A. Seifert. 1989. Sera and conditioned media contain different isoforms of platelet-derived growth factor (PDGF) which bind to different classes of PDGF receptor. J. Biol. Chem. 264:2502-2508.
- Campion, D. R. 1984. The muscle satellite cell: a review. Int. Rev. Cytol. 87:225-251.
- Clegg, C. H., T. A. Linkhart, B. B. Olwin, and S. Hauschka. 1987. Growth factor control of skeletal muscle differentiation: commitment to terminal differentiation occurs in G1 phase and is repressed by fibroblast growth factor. J. Cell Biol. 105:949-956.
- DiMario, J., and R. C. Strohman. 1988. Satellite cells from dystrophic (mdx) mouse muscle are stimulated by fibroblast growth factor in vitro. *Differentia-tion*. 39:42–49.
- Florini, J. R., and K. A. Magri. 1989. Effects of growth factors on myogenic differentiation. Am. J. Physiol. 256:C701-C711.
- Grotendorst, G. R., T. Chang, H. E. J. Seppä, H. K. Kleinman, and G. R. Martin. 1982. Platelet-derived growth factor is a chemoattractant for vascular smooth muscle cell. J. Cell. Physiol. 113:261–266.
- Hammacher, A., K. Mellström, C.-H. Heldin, and B. Westermark. 1989. Isoform-specific induction of actin reorganization by platelet-derived growth factor suggests that the functionally active receptor is a dimer. *EMBO (Eur. Mol. Biol. Organ.) J.* 8:2489-2495.
- Hart, C. E., J. W. Forstrom, J. D. Kelly, R. A. Seifert, R. A. Smith, R. Ross, M. J. Murray, and D. F. Bowen-Pope. 1988. Two classes of PDGF receptors recognize different isoforms of PDGF. *Science (Wash. DC)*. 240:1529– 1531.
- Hart, I. K., W. D. Richardson, S. R. Bolsover, and M. C. Raff. 1989. PDGF and intracellular signaling in the timing of oligodendrocyte differentiation. J. Cell Biol. 109:3411-3417.
- Heldin, C.-H., and B. Westermark. 1989. Platelet-derived growth factors: a family of isoforms that bind to two distinct receptors. *Br. Med. Bull.* 45:453-464.
- Heldin, C.-H., G. Bäckström, A. Östman, A. Hammacher, L. Rönnstrand, K. Rubin, M. Nister, and B. Westermark. 1988. Binding of different dimeric

forms of PDGF to human fibroblasts: evidence for two separate receptor types. EMBO (Eur. Mol. Biol. Organ.) J. 7:1387-1394.

- Heldin, C.-H., A. Ernlund, C. Rorsman, and L. Rönnstrand. 1989. Dimerization of B-type platelet-derived growth factor receptors occur after ligand binding and is closely associated with receptor kinase activation. J. Biol. Chem. 264:8905-8912.
- Jennische, E., A. Skottner, and H.-A. Hansson. 1987. Satellite cells express the trophic factor IGF-I in regenerating skeletal muscle. Acta Physiol. Scand. 129:9–15.
- Jin, P., M. Rahm, L. Claesson-Welsh, C.-H. Heldin, and T. Sejerson. 1990. Expression of PDGF A-chain and B-receptor genes during rat myoblast differentiation. J. Cell Biol. 110:1665-1672.
- Linkhart, T. A., R. W. Lim, and S. D. Hauschka. 1982. Regulation of normal and variant mouse myoblast proliferation and differentiation by specific growth factors. *In* Growth of Cells in Hormonally Defined Media. G. H. Sato, A. B. Pardee, and D. A. Sirbasku, editors. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York. 867-876.
- Mauro, A. 1979. Muscle Regeneration. Raven Press, New York. 560 pp.
- Moss, F. P., and C. P. Leblond. 1971. Satellite cells as a source of nuclei in muscles of growing rats. Anat. Rec. 170:421-436.
- Partridge, T. A., J. E. Morgan, S. E. Moore, and F. S. Walsh. 1988. Myogenesis in vivo from the mouse C2 muscle cell-line. J. Cell. Biochem. Suppl. 12C:331.
- Raines, E. W., and R. Ross. 1982. Platelet-derived growth factor. I. High yield purification and evidence for multiple forms. J. Biol. Chem. 257:5154– 5160.
- Ross, R., E. W. Raines, and D. F. Bowen-Pope. 1986. The biology of plateletderived growth factor. Cell. 46:155-169.
- Saad, A. D., T. Obinata, and D. A. Fischman. 1987. Immunochemical analysis of protein isoforms in thick myofilaments of regenerating skeletal muscle. *Dev. Biol.* 119:336-349.
- Schultz, E., M. C. Gibson, and T. Champion. 1978. Satellite cells are mitotically quiescent in mature mouse muscle: an EM and radioautographic study. J. Exp. Zool. 206:451-456.
- Schultz, E., D. J. Albright, D. L. Jaryszak, and T. L. David. 1988. Survival of satellite cells in whole muscle transplants. Anat. Rec. 222:12-17.
- Seifert, R. A., C. E. Hart, P. E. Phillips, J. W. Forstrom, R. Ross, M. J. Murray, and D. F. Bowen-Pope. 1989. Two different subunits associate to create isoform-specific platelet-derived growth factor receptors. J. Biol. Chem. 264:8771-8778.
- Seppä, H., G. Grotendorst, S. Seppä, E. Schiffman, and G. R. Martin. 1982. Platelet-derived growth factor is chemotactic for fibroblasts. J. Cell Biol. 92:584-588.
- Snow, M. H. 1977. Myogenic cell formation in regenerating rat skeletal muscle injured by mincing. II. An autoradiographic study. Anat. Rec. 188:201-218.
- Venkatasubramanian, K., and M. Solursh. 1984. Chemotactic behavior of myoblasts. Dev. Biol. 104:428-433.
- Watt, D. J., J. E. Morgan, M. A. Clifford, and T. A. Partridge. 1987. The movement of muscle precursor cells between adjacent regenerating muscles in the mouse. *Anat. Embryol.* 175:527–536.
- Yablonka-Reuveni, Z., and M. Nameroff. 1987. Skeletal muscle cell populations: separation and partial characterization of fibroblast-like cells from embryonic tissue using density centrifugation. *Histochemistry*. 87:27-38.
- Yablonka-Reuveni, Z., L. S. Quinn, and M. Nameroff. 1987. Isolation and clonal analysis of satellite cells from chicken pectoralis muscle. *Dev. Biol.* 119:252-259.
- Yablonka-Reuveni, Z., S. K. Anderson, D. F. Bowen-Pope, and M. Nameroff. 1988. Biochemical and morphological differences between fibroblasts and myoblasts from embryonic chicken skeletal muscle. *Cell Tissue Res.* 252: 339-348.
- Yablonka-Reuveni, Z., D. F. Bowen-Pope, and R. S. Hartley. 1990. Proliferation and differentiation of myoblasts: the role of platelet-derived growth factor and the basement membrane. *In* The Dynamic State of Muscle Fibers. D. Pette, editor. Walter de Gruyter & Co., Berlin. 693-706.
- Yaffe, D. 1973. Rat skeletal muscle cells. In Tissue Culture: Methods and Applications. P. F. Krause, and M. K. Patterson, editors. Academic Press, New York. 106-114.
- Yaffe, D., and O. Saxel. 1977. Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. *Nature (Lond.)*. 270:725-727.
- Zadeh, B. J., A. González-Sánchez, D. A. Fischman, and D. Bader. 1986. Myosin heavy chain expression in embryonic cardiac cell cultures. *Dev. Biol.* 115:204-214.